CRISPR RNAs trigger innate immune responses in human cells

CRISPR RNAs trigger innate immune responses in human cells

Kim S, Koo T, Jee HG, Cho HY, Lee G, Lim DG, Shin HS, Kim JS.
Genome Res. 2018 Feb 22.

OTS2021-08-03T13:53:09+00:00

Related Posts

Targeted suicide gene therapy for liver cancer based on ribozyme-mediated RNA replacement through post-transcriptional regulation

Targeted suicide gene therapy for liver cancer based on ribozyme-mediated RNA replacement through post-transcriptional regulation

April 23rd, 2021

Hovlinc is a recently evolved class of ribozyme found in human lncRNA

Hovlinc is a recently evolved class of ribozyme found in human lncRNA

April 23rd, 2021

Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents

Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents

March 15th, 2021

In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice

In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice

February 16th, 2021

Screening for functional circular RNAs using the CRISPR-Cas13 system

Screening for functional circular RNAs using the CRISPR-Cas13 system

January 30th, 2021

Evaluation of Engineered CRISPR-Cas-Mediated Systems for Site-Specific RNA Editing

Evaluation of Engineered CRISPR-Cas-Mediated Systems for Site-Specific RNA Editing

January 30th, 2021

Subscribe to our Newsletter

Oligonucleotide Therapeutics Society

Oligonucleotide Therapeutics Society

3960 W Point Loma Blvd, Suite H
Box 346
San Diego, CA 92110

info@oligotherapeutics.org

Terms & Conditions

Resources

Stay Connected

Search

Subscribe in a reader

© Copyright 2012 – 2024 | Oligotherapeutics.org | All Rights Reserved | Finfrock Marketing

Enter Username or Email Address:
Password:
Forgot Password | Sign Up

Save Password

First Name *
Last Name *
Username *
Email *
Password *
Confirm Password *
Phone:
Organization Name
Select Sectors

Already have an account? Login

This website uses cookies and third party services. Ok